Part 2: Latest Stroke Science
What we learned at the International Stroke Conference (ISC20)
Here’s the conference video if you want to listen to the highlights!Missed Part 1? Here’s my first ISC2020 Takeaway
Here are the studies that were featured at ISC20 with a summary of results
The Randomized Study of Endovascular Therapy With versus Without Intravenous Tissue Plasminogen Activator in Acute Stroke With ICA and M1 Occlusion (SKIP Study)
Kentaro Suzuki, Nippon Medical School, Tokyo, Japan
- RESULTS: 90-day favorable outcomes rate was not significantly different for EVT with versus without intravenous tPA in acute stroke with large vessel occlusion. Noninferiority of direct EVT to bridging therapy was not demonstrated.
Comparative Effectiveness of Home BP Telemonitoring plus Nurse Case Management (HBPTM+NCM) versus HBPTM Alone on Systolic BP (SBP) Reduction among Minority Stroke Survivors
Gbenga Ogedegbe | NYU School of Medicine, New York, NY
- RESULTS: A greater reduction in systolic BP was seen in minority stroke survivors when home BP telemonitoring was combined with nurse case management (HBPTM+NCM) versus HBPTM alone.
- Ogedegbe’s Abstract
The Spot Sign and Tranexamic Acid on Preventing ICH Growth – Australasia Trial (STOP-AUST): A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Nawaf Yassi | Dept. of Medicine and Neurology, Melbourne Brain Center @ Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
- RESULTS: A non-statistically significant reduction was seen in intracerebral hemorrhage (ICH) when tranexamic acid (TXA) was given to spot sign positive patients within 4.5 hours of ICH onset. A trend toward reduced ICH growth in those treated “ultra-early” (≤3h and ≤2h) warrants more study.
Cilostazol versus Other Anti-platelet Drugs for the In-stent Restenosis After Carotid Artery Stenting: The Carotid Artery Stenting With Cilostazol Addition for Restenosis (CAS-CARE) Trial
Hiroshi Yamagami | National Hospital Organization Osaka National Hospital, Osaka, Japan
- RESULTS: The addition of cilostazol to other anti-platelet drugs in CAS patients inhibited carotid in-stent restenosis (ISR) more than in the non-cilostazol group within two years of CAS.
- Yamagami’s Abstract
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or PCI in Patients With Atrial Fibrillation and Prior Stroke: Insights From the AUGUSTUS Trial
M. Cecilia Bahit | INECO Neurociencias, Rosario, Argentina
- RESULTS: Insights from the AUGUSTUS trial: with or without a history of stroke, TIA, or TE, apixaban safety and efficacy compared to vitamin K antagonists (VKA) was consistent with the major trial results.
- Bahit’s Abstract
World First Robotic Neurovascular Intervention Experience: Opening the Doors to Remote Procedures
Vitor Mendes Pereira | Toronto Western Hospital, Toronto, ON, Canada
- RESULTS: World?s first robotic neurovascular intervention case experiences offer the potential for major impact on future endovascular stroke treatment.
- Pereira’s Abstract